Embla Medical hf. (LON:0FIW)

London flag London · Delayed Price · Currency is GBP · Price in DKK
26.70
0.00 (0.00%)
At close: Jul 16, 2026
Market Cap1.29B -20.2%
Revenue (ttm)725.72M +11.7%
Net Income64.85M +18.6%
EPS0.15 +19.1%
Shares Out n/a
PE Ratio19.82
Forward PE18.09
Dividendn/a
Ex-Dividend Daten/a
Volume4
Open26.70
Previous Closen/a
Day's Range26.70 - 26.70
52-Week Range25.90 - 36.40
Beta0.58
Analystsn/a
Price Targetn/a
Earnings DateJul 21, 2026

About Embla Medical

Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. The Prosthetics and Neuro Orthotics segment offers mechanical products, such as lower and upper limb loss or difference; and bionic products, such as microprocessor-controlled feet, knees, hands, fingers, and neuro orthotic joints. The Bracing and Supports segment provides os... [Read more]

Industry Orthopedic, Prosthetic, and Surgical Appliances and Supplies
Founded 1971
Employees 4,500
Stock Exchange London Stock Exchange
Ticker Symbol 0FIW

Financial Performance

In 2025, Embla Medical's revenue was $928.69 million, an increase of 8.63% compared to the previous year's $854.89 million. Earnings were $83.34 million, an increase of 22.05%.

Financial numbers in USD Financial Statements

News

Embla Medical Slides: R&D presentation

Embla Medical has posted slides in relation to its latest quarterly earnings report, which was published on June 24, 2026.

24 days ago - Filings

Embla Medical Earnings Call Transcript: Q1 2026

Q1 2026 saw 15% revenue growth (4% organic), stable margins despite tariffs and FX, and 21% bottom-line growth. Guidance for 5%-8% organic growth and 20%-22% EBITDA margin is reiterated, with segment strength in Prosthetics and neuro-orthotics and recovery expected in Patient Care.

2 months ago - Transcripts

Embla Medical Quarterly report: Q1 2026

Embla Medical has published its Q1 2026 quarterly earnings report on April 28, 2026.

2 months ago - Filings

Embla Medical Slides: Q1 2026

Embla Medical has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 28, 2026.

2 months ago - Filings

Embla Medical Earnings Call Transcript: Q1 2026

Q1 2026 saw 15% reported sales growth and 21% net profit growth, with strong Prosthetics & Neuro Orthotics performance and margin pressure from FX and tariffs. Full-year guidance for 5%-8% organic growth and 20%-22% EBITDA margin is reiterated.

2 months ago - Transcripts

Embla Medical Quarterly report: Q1 2026

Embla Medical has published its Q1 2026 quarterly earnings report on April 28, 2026.

2 months ago - Filings

Embla Medical Slides: Q1 2026

Embla Medical has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 28, 2026.

2 months ago - Filings

Embla Medical Slides: Investor presentation

Embla Medical has posted slides in relation to its latest quarterly earnings report, which was published on April 28, 2026.

2 months ago - Filings

Embla Medical Transcript: Life Science-dagen 2026

A global leader in mobility solutions is driving growth through innovation, acquisitions, and expanding access to advanced prosthetics and neuro-orthotics. Key growth comes from functional trade-up, recurring sales, and new market penetration, while challenges include reimbursement, tariffs, and geopolitical risks.

4 months ago - Transcripts

Embla Medical Slides: FY 2026

Embla Medical has posted slides in relation to its FY 2026 quarterly earnings report, which was published on March 4, 2026.

4 months ago - Filings

Embla Medical Earnings Call Transcript: Q4 2025

Solid organic and acquisition-driven growth was achieved, with strong cash flow and resilient margins despite tariffs and FX headwinds. Guidance for 2026 anticipates 5%-8% organic growth and 20%-22% EBITDA margin, supported by efficiency gains and new product launches.

5 months ago - Transcripts

Embla Medical Annual report: Q4 2025

Embla Medical has published its Q4 2025 annual report on February 3, 2026.

5 months ago - Filings

Embla Medical Quarterly report: Q4 2025

Embla Medical has published its Q4 2025 quarterly earnings report on February 3, 2026.

5 months ago - Filings

Embla Medical Slides: Q4 2025

Embla Medical has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 3, 2026.

5 months ago - Filings

Embla Medical Earnings Call Transcript: Q4 2025

Solid organic sales growth of 6% for 2025 was driven by strong performance in prosthetics and neuroorthotics, with robust cash flow and a stable EBITDA margin. 2026 guidance targets 5%-8% organic growth and a 20%-22% EBITDA margin, with continued focus on patient care improvements and managing external headwinds.

5 months ago - Transcripts

Embla Medical Annual report: Q4 2025

Embla Medical has published its Q4 2025 annual report on February 3, 2026.

5 months ago - Filings

Embla Medical Quarterly report: Q4 2025

Embla Medical has published its Q4 2025 quarterly earnings report on February 3, 2026.

5 months ago - Filings

Embla Medical Slides: Q4 2025

Embla Medical has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 3, 2026.

5 months ago - Filings

Embla Medical Slides: Investor presentation

Embla Medical has posted slides in relation to its latest quarterly earnings report, which was published on February 3, 2026.

5 months ago - Filings

Embla Medical hf: Interim Report Q4 and Full Year 2025

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026 Interim Report Q4 and Full Year 2025 Sveinn Sölvason, President and CEO, comments: "We delivered solid sales in the fourth qua...

5 months ago - PRNewsWire

Embla Medical Slides: SEB Nordic Seminar presentation

Embla Medical has posted slides in relation to its latest quarterly earnings report, which was published on January 9, 2026.

6 months ago - Filings

Embla Medical Slides: Investor presentation

Embla Medical has posted slides in relation to its latest quarterly earnings report, which was published on December 11, 2025.

7 months ago - Filings

Embla Medical Earnings Call Transcript: Q3 2025

Q3 2025 saw 7% organic and 11% reported sales growth, led by double-digit gains in prosthetics and neuroorthotics, while patient care and bracing/supports lagged. EBITDA margin held at 22%, and full-year guidance for 5%-6% organic growth and 20%-21% EBITDA margin was reiterated.

9 months ago - Transcripts

Embla Medical Quarterly report: Q3 2025

Embla Medical has published its Q3 2025 quarterly earnings report on October 21, 2025.

9 months ago - Filings

Embla Medical Slides: Q3 2025

Embla Medical has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 21, 2025.

9 months ago - Filings